Related Experiment Video

Updated: Apr 1, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.7K

Everolimus in the Treatment of Metastatic Breast Cancer

Melanie E Royce1, Diaa Osman1

  • 1Multidisciplinary Breast Cancer Clinic and Program, University of New Mexico Cancer Center, Albuquerque, NM, USA.

Breast Cancer : Basic and Clinical Research
|September 30, 2015
PubMed

Insights

The mammalian target of rapamycin (mTOR) pathway is crucial in breast cancer. The mTOR inhibitor everolimus shows promise in improving outcomes for specific metastatic breast cancer subtypes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway plays a significant role in breast cancer development and progression.
  • Dysregulation of the mTOR pathway is implicated in various cancer types, including breast cancer.

Purpose of the Study:

  • To review clinical trial findings on the efficacy of the mTOR inhibitor everolimus in metastatic breast cancer.
  • To explore emerging research avenues for everolimus in breast cancer treatment.

Main Methods:

  • Systematic review of published clinical trials investigating everolimus in metastatic breast cancer.
  • Analysis of patient outcomes and response rates in trials involving everolimus.

Main Results:

  • Everolimus has demonstrated clinical benefit in specific subtypes of metastatic breast cancer, particularly hormone receptor-positive, HER2-negative disease.
  • Trials indicate improved patient outcomes when everolimus is used after progression on prior endocrine therapy.

Conclusions:

  • Everolimus is a valuable therapeutic option for select patients with metastatic breast cancer.
  • Further research is warranted to optimize the use of everolimus and explore novel therapeutic strategies targeting the mTOR pathway.
Keywords:
endocrine resistanceeverolimushormone receptor–positivemTOR

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

846
Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts07:50

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

9.0K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
562
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K